The transaction terms involve Jazz commencing an all-cash tender offer to acquire all outstanding shares of Chimerix’s common ...

At the heart of the deal is the drug candidate dordaviprone, which is months away from a regulatory verdict for its use in H3 ...

Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors--Transaction to add near-term commercial ...

About Dordaviprone Dordaviprone (ONC201) is a first-in-class small molecule imipridone that targets the mitochondrial protease ClpP and dopamine receptor D2 (DRD2), reversing H3 K27me3-loss in H3 K27M ...

I have 170,000 miles on my 2008 H3. I get about 19 to 20 MPG and it does not burn one drop of oil. The 5-cylinder engine runs great and the car performs like new. Off road, it is a beast and ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...

A New Drug Application has been accepted seeking accelerated approval for dordaviprone for patients with recurrent H3 ...

At this time, I would like to welcome everyone to Harmony Biosciences fourth quarter and full-year 2024 financial results ...

The FDA has granted a priority review to dordaviprone for treating patients with recurrent H3K27M-mutant diffuse glioma, a ...

The leading Extensive-Stage Small Cell Lung Cancer Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, ...

Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S.

Shares of Chimerix (NASDAQ: NASDAQ: CMRX) climbed 12.5% as the company announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for dordaviprone, a potential ...